New combo aims to shrink rare lung tumors

NCT ID NCT07357623

First seen Jan 22, 2026 · Last updated May 14, 2026 · Updated 18 times

Summary

This study tests whether adding chemotherapy to the drug surufatinib works better than surufatinib alone for people with a rare type of lung cancer called pulmonary neuroendocrine tumor. About 96 adults will be randomly assigned to one of two treatment groups. The goal is to see if the combination can shrink tumors more effectively and safely.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking Union Medical College Hospital

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, 100000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shanghai chest hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The First Affiliated Hospital Of Anhui Medical University

    NOT_YET_RECRUITING

    Hefei, Anhui, 230000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Zhengzhou University

    NOT_YET_RECRUITING

    Zhengzhou, Henan, 450000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.